Cell No. : Cell Name RCB0708 : HF10B4  update : 2024/01/17
Comment			Anti-human lung carcinoma mAb (IgM). Possible to culture in serum-free medium.
Comment from the depositor
Terms and conditions			There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Remarks
Order Form			Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)
			Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
	Basic information	Depositor	Shirahata, Sanetaka
		Originator	Murakami, Hiroki
		Year of deposit	1991
		Animal	_human x human < Hybrid
		Tissue	hybridoma
		Classification	hybrid cells
		Lifespan	infinite
		Morphology	lymphocyte-like
		Cellosaurus(Expasy)	CVCL_C473
	hybridoma	Fusion_cell_1 name	lymphocyte
		Fusion_cell_1 strain	human
		Fusion_cell_2 name	NAT-30
		Fusion_cell_2 strain	human
		Fusion method	PEG, HAT selection
		Antibody name	HF10B4
		Subclass	IgM
		Immunogen	human lymphocytes from lymph nodes of lung carcino
		Antigen_name	human lung carcinoma
			deposit info	lot info
		Medium	Medium List
		Culture type		Suspension cells
		Culture medium		E-RDF + 10% FBS
		Culture method
		Antibiotics		Free
		Passage method		dilution
	Culture information	Passage ratio		1 : 10 split
		SC frequency		Subculture : 3 times/week
		Temperature		37 ℃
		CO2 concentration		5 %
		Freeze medium		Medium + 10% DMSO
		Freezing method		Slow freezing
		Mycoplasma		(-)
		Antibody subclass		IgM
		Chromosome mode		46-49(50) : 46(1),47(14),48(31),49(4)
Reference information		Reference	6
		User's Publication	1

Top

Reference

272  Sugahara T, Nakajima H, Shirahata S, Murakami H.  Purification and characterization of immunoglobulin production stimulating factor-II beta derived from Namalwa cells  Cytotechnology  1992  10(2):137-46  PubMed ID: 1369209   DOI: 10.1007/BF00570890

270  Tachibana H, Akiyama K, Shirahata S, Murakami H.   Altered reactivity of immunoglobulin produced by human-human hybridoma cells transfected by pSV2-neo gene  Cytotechnology   1991  6(3):219-26  PubMed ID: 1369345   DOI: 10.1007/BF00624760

271  Shirahata S, Tachibana H, Mori T, Seki K, Yamada K, Murakami H.  Changes in specificities of human monoclonal antibodies by introduction of drug-resistance gene into hybridomas  Agric Biol Chem  1991  55(6):1689-91  PubMed ID: 1368708

269  Toyoda K, Sugahara T, Inouye K, Yamada K, Shirahata S, Murakami H.  Purification and characterization of immunoglobulin production stimulating factor derived from human B lymphoblastoid HO-323 cells  Cytotechnology  1990  3(2):189-97  PubMed ID: 1366596   DOI: 10.1007/BF00143681

273  Yamada K, Akiyoshi K, Murakami H,  Partial purification and characterization of immunoglobulin production stimulating factor derived from Namalwa cells  In Vitro Cell Dev Biol  1989  25(3 Pt 1):243-7.  PubMed ID: 2925563   DOI: 10.1007/BF02628461

1460  Murakami H, Hashizume S, Ohashi H, Shinohara K, Yasumoto K, Nomoto K, Omura H  Human-human hybridomas secreting antibodies specific to human lung carcinoma.  In Vitro Cell Dev Biol  1985  21:593-6  PubMed ID: 3902783   DOI: 10.1007/BF02620891

Top

User's Publication

3571  Mikami S, Kobayashi T, Yokoyama S, Imataka H.  A hybridoma-based in vitro translation system that efficiently synthesizes glycoproteins.  J Biotechnol  2006  127(1):65-78  PubMed ID: 16889861   DOI: 10.1016/j.jbiotec.2006.06.018